Oxidative stress and body composition in prostate cancer and benign prostatic hyperplasia patients
- PMID: 25202090
Oxidative stress and body composition in prostate cancer and benign prostatic hyperplasia patients
Abstract
Objective: To investigate the role of body composition and oxidative stress measured by total thiol groups (TTG) levels in prostate specimens of patients affected by benign prostatic hyperplasia (BPH) or prostate cancer (PCa).
Patients and methods: From January 2011 to January 2013, a cohort of 150 consecutive male patients who underwent first prostate biopsy were enrolled. Twelve-core needle biopsy was performed as standard procedure, while twelve more needle tissue cores matched with the previous group were also collected for glutathione determination. After definitive diagnosis, measurement of glutathione was performed in the correspondent one matched prostatic sample where PCa or BPH were identified. A day after the prostatic biopsy, body composition was estimated by air plethysmography (BOD POD®).
Results: A significant difference of TTG was observed in BPH and PCa patients; 34 nanomole (nmol) reagent sulfihydrylc (RSH)/ mg protein vs. 1.1 nmol RSH/ mg protein respectively (p<0.05). In BPH patients, a negative correlation was found between TTG and age (r=-0.46; p<0.05), while, in PCa patients, a positive correlation was observed between TTG and fat mass (FM) (r=0.76; p<0.01) and waist circumference (WC) (r=0.49; p<0.05). Multivariate linear regression analysis showed TTG to be negatively associated with age (β-coefficient=-0.4; p<0.05) in BPH patients and positively with FM (β-coefficient=3.4; p<0.01) and WC (β-coefficient=2.7; p<0.05) in PCa patients.
Conclusion: Aging determines a progressive reduction of TTG in BPH patients, while in PCa subjects glutathione concentrations are significantly lower and FM and WC are associated with an unbalance of its levels.
Keywords: Benign prostatic hyperplasia; aging; fat mass; glutathione S-transferase; oxidative stress; prostate cancer.
Copyright© 2014 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.
Similar articles
-
Calculated fast-growing benign prostatic hyperplasia--a risk factor for developing clinical prostate cancer.Scand J Urol Nephrol. 2002;36(5):330-8. doi: 10.1080/003655902320783827. Scand J Urol Nephrol. 2002. PMID: 12487736
-
Prostate stem cell antigen mRNA expression in preoperatively negative biopsy specimens predicts subsequent cancer after transurethral resection of the prostate for benign prostatic hyperplasia.Prostate. 2009 Sep 1;69(12):1292-302. doi: 10.1002/pros.20973. Prostate. 2009. PMID: 19462463
-
[Differences in pathological features of histological inflammation between benign prostatic hyperplasia and prostate cancer].Sichuan Da Xue Xue Bao Yi Xue Ban. 2013 Sep;44(5):760-3, 768. Sichuan Da Xue Xue Bao Yi Xue Ban. 2013. PMID: 24325107 Chinese.
-
The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation.Eur Urol. 2011 Jul;60(1):106-17. doi: 10.1016/j.eururo.2011.03.055. Epub 2011 Apr 9. Eur Urol. 2011. PMID: 21497433 Review.
-
Is there evidence of a relationship between benign prostatic hyperplasia and prostate cancer? Findings of a literature review.Eur Urol. 2009 Apr;55(4):864-73. doi: 10.1016/j.eururo.2008.11.011. Epub 2008 Nov 21. Eur Urol. 2009. PMID: 19027219 Review.
Cited by
-
Body Composition and Prostate Cancer Risk: A Systematic Review of Observational Studies.Adv Nutr. 2022 Aug 1;13(4):1118-1130. doi: 10.1093/advances/nmab153. Adv Nutr. 2022. PMID: 34918023 Free PMC article.
-
Thiol Groups as a Biomarker for the Diagnosis and Prognosis of Prostate Cancer.Sci Rep. 2020 Jun 4;10(1):9093. doi: 10.1038/s41598-020-65918-w. Sci Rep. 2020. PMID: 32499542 Free PMC article.
-
Mangosteen pericarp components alleviate progression of prostatic hyperplasia and mitochondrial dysfunction in rats.Sci Rep. 2020 Jan 15;10(1):322. doi: 10.1038/s41598-019-56970-2. Sci Rep. 2020. PMID: 31941927 Free PMC article.
-
Oxidative Stress Links Aging-Associated Cardiovascular Diseases and Prostatic Diseases.Oxid Med Cell Longev. 2021 Jul 17;2021:5896136. doi: 10.1155/2021/5896136. eCollection 2021. Oxid Med Cell Longev. 2021. PMID: 34336107 Free PMC article. Review.
-
Serum deprivation initiates adaptation and survival to oxidative stress in prostate cancer cells.Sci Rep. 2020 Jul 27;10(1):12505. doi: 10.1038/s41598-020-68668-x. Sci Rep. 2020. PMID: 32719369 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical